CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 258 enrolled
Drug / intervention
Rotigotinedrug
Likely dose
Rotigotine 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00594386
NCT00594386Phase 3Completed
CompareCT.gov

An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.

UCB Pharma·interventional·Posted Jan 15, 2008·Updated Oct 2, 2014

In Brief

A Phase 3 clinical trial evaluating Rotigotine for Parkinson's Disease. Completed, enrolled 258 participants across 41 sites in 2 countries.

Detailed Summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 15, 2008
Enrollment StartAug 1, 2002
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 18.5 years ago

Interventions

Rotigotinedrug

Rotigotine transdermal patches: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours. After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.